Clinical Trials
SAGA Diagnostics Extends its Collaboration with Servier to Use Ultrasensitive SAGAsafe Technology in Cancer Clinical Trials
SAGA Diagnostics AB, a cancer liquid biopsy and genomic testing company focused on precision oncology and non-invasive ultrasensitive monitoring of cancer patients, announces it has...
Clinical Trials
PHARMASEAL Celebrates A Year of Significant Success as it Prepares for Exciting Program of Industry Conferences in 2020
PHARMASEAL, a new provider of clinical trial management (CTMS) and governance solutions to enter the market, is celebrating a year of significant success, with 2019...
Clinical Trials
Bionetix, ProQinase, and MercachemSyncom Announce a Joint Research Project from Target Identification to Clinical Study
Bionetix, a biotech company developing novel oncology drugs; ProQinase, an oncology-focused contract research organization (CRO) recently acquired by Reaction Biology Corporation (Malvern/PA, USA); and MercachemSyncom,...
Clinical Trials
New High Precision Digital Reagent Dispensers Facilitate Assay Miniaturization and Increased Throughput
Scientists working across drug metabolism and pharmacokinetics, bioanalytical, pre-clinical and clinical trial applications can now access a range of digital reagent dispensers designed to enable...
Clinical Trials
Epizyme Announces U.S. FDA Approval of TAZVERIK for the Treatment of Patients with Epithelioid Sarcoma
Epizyme, Inc., a biopharmaceutical company developing novel epigenetic therapies, announced that the U.S. FDA has granted accelerated approval of TAZVERIK for the treatment of adults...
Clinical Trials
Greenphire Expands ConneX Global Travel Solution to Further Support Clinical Trial Participation and Retention Worldwide
Greenphire, the global leader in financial software for clinical trials, announced that it has expanded its ConneX global travel solution to include additional in-market support...
Clinical Trials
VBI Vaccines Announces Second Pivotal Phase 3 Study of Sci-B-Vac Meets Primary and Secondary Endpoints
VBI Vaccines Inc. (VBI), a commercial-stage biopharmaceutical company developing next-generation infectious disease and immuno-oncology vaccines, reported top-line data from CONSTANT, the second pivotal Phase 3...
Subscribe
- Never miss a story with notifications
- Gain full access to our premium content
- Browse free from any location or device.